UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interests
Balance at beginning of period at Dec. 31, 2020	$ 974.3	$ 961.2	$ 1.7	$ (667.0)	$ 216.3	$ 1,406.5	$ 3.7	$ 13.1
Balance (in shares) at Dec. 31, 2020			151,987,081	22,058,529
Increase (Decrease) in Stockholders' Equity
Stock options exercised	1.2	1.2			1.2
Stock options exercised (in shares)			65,312
Restricted Stock units vested	(0.1)	(0.1)			(0.1)
Restricted Stock units vested (in shares)			21,821
Stock based compensation	3.4	3.4			3.4
Shares Repurchased	(32.8)	(32.8)		$ (32.8)
Shares Repurchased (in shares)			(530,729)	530,729
Cash dividends paid to common shareholders	(6.1)	(6.1)				(6.1)
Consolidated net income	57.8	56.7				56.7		1.1
Other comprehensive loss	(16.0)	(15.8)					(15.8)	(0.2)
Balance at end of period at Mar. 31, 2021	981.7	967.7	$ 1.7	$ (699.8)	220.8	1,457.1	(12.1)	14.0
Balance (in shares) at Mar. 31, 2021			151,543,485	22,589,258
Increase (Decrease) in Stockholders' Equity
Stock options exercised	1.0	1.0			1.0
Stock options exercised (in shares)			64,783
Restricted Stock units vested (in shares)			1,780
Stock based compensation	3.6	3.6			3.6
Shares Repurchased	(38.3)	(38.3)		$ (38.3)
Shares Repurchased (in shares)			(555,576)	555,576
Cash dividends paid to common shareholders	(6.0)	(6.0)				(6.0)
Formation of Acuity Spatial Genomics Inc.									$ 0.3
Consolidated net income	58.7	57.6				57.6		1.1
Other comprehensive loss	14.7	16.4					16.4	(1.7)
Balance at end of period at Jun. 30, 2021	1,015.4	1,002.0	$ 1.7	$ (738.1)	225.4	1,508.7	4.3	13.4	0.3
Balance (in shares) at Jun. 30, 2021			151,054,472	23,144,834
Increase (Decrease) in Stockholders' Equity
Stock options exercised	8.3	8.3			8.3
Stock options exercised (in shares)			385,597
Restricted Stock units vested	(4.5)	(4.5)			(4.5)
Restricted Stock units vested (in shares)			250,595
Stock based compensation	3.8	3.8			3.8
Cash dividends paid to common shareholders	(6.1)	(6.1)				(6.1)
Consolidated net income	88.1	87.1				87.1		1.0
Other comprehensive loss	(15.4)	(15.0)					(15.0)	(0.4)
Balance at end of period at Sep. 30, 2021	1,089.6	1,075.6	$ 1.7	$ (738.1)	233.0	1,589.7	(10.7)	14.0	0.3
Balance (in shares) at Sep. 30, 2021			151,690,664	23,144,834
Balance at beginning of period at Dec. 31, 2021	1,084.6	1,070.5	$ 1.7	$ (820.3)	237.8	1,659.5	(8.2)	14.1	0.2
Balance (in shares) at Dec. 31, 2021			150,753,687	24,151,348
Increase (Decrease) in Stockholders' Equity
Stock options exercised	3.1	3.1			3.1
Stock options exercised (in shares)			118,630
Restricted Stock units vested (in shares)			22,440
Stock based compensation	3.8	3.8			3.8
Shares Repurchased	(105.6)	(105.6)		$ (105.6)
Shares Repurchased (in shares)			(1,603,055)	1,603,055
Cash dividends paid to common shareholders	(7.5)	(7.5)				(7.5)
PreOmics Acquisition - other shareholders									6.8
Consolidated net income	62.1	61.6				61.6		0.5
Other comprehensive loss	(9.2)	(8.9)					(8.9)	(0.3)	(0.2)
Balance at end of period at Mar. 31, 2022	1,031.3	1,017.0	$ 1.7	$ (925.9)	244.7	1,713.6	(17.1)	14.3	6.8
Balance (in shares) at Mar. 31, 2022			149,291,702	25,754,403
Balance at beginning of period at Dec. 31, 2021	1,084.6	1,070.5	$ 1.7	$ (820.3)	237.8	1,659.5	(8.2)	14.1	0.2
Balance (in shares) at Dec. 31, 2021			150,753,687	24,151,348
Balance at end of period at Sep. 30, 2022	948.0	937.0	$ 1.7	$ (1,058.6)	250.1	1,835.9	(92.1)	11.0	5.7
Balance (in shares) at Sep. 30, 2022			147,366,634	27,931,042
Balance at beginning of period at Mar. 31, 2022	1,031.3	1,017.0	$ 1.7	$ (925.9)	244.7	1,713.6	(17.1)	14.3	6.8
Balance (in shares) at Mar. 31, 2022			149,291,702	25,754,403
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.2	0.2			0.2
Stock options exercised (in shares)			14,110
Restricted Stock units vested (in shares)			1,811
Stock based compensation	3.8	3.8			3.8
Shares Repurchased	(60.3)	(60.3)		$ (60.3)
Shares Repurchased (in shares)			(983,741)	983,741
Cash dividends paid to common shareholders	(7.5)	(7.5)				(7.5)
Consolidated net income	49.9	49.5				49.5		0.4	(0.2)
Other comprehensive loss	(33.0)	(32.2)					(32.2)	(0.8)	(0.3)
Balance at end of period at Jun. 30, 2022	984.4	970.5	$ 1.7	$ (986.2)	248.7	1,755.6	(49.3)	13.9	6.3
Balance (in shares) at Jun. 30, 2022			148,323,882	26,738,144
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.6	0.6			0.6
Stock options exercised (in shares)			30,699
Restricted Stock units vested	(3.1)	(3.1)			(3.1)
Restricted Stock units vested (in shares)			204,951
Stock based compensation	3.9	3.9			3.9
Shares Repurchased	(72.4)	(72.4)		$ (72.4)
Shares Repurchased (in shares)			(1,192,898)	1,192,898
Cash dividends paid to common shareholders	(7.4)	(7.4)				(7.4)
Consolidated net income	88.6	88.1				88.1		0.5	(0.2)
Acquisition of minority interest	(3.2)	(0.6)				(0.4)	(0.2)	(2.6)
Other comprehensive loss	(43.4)	(42.6)					(42.6)	(0.8)	(0.4)
Balance at end of period at Sep. 30, 2022	$ 948.0	$ 937.0	$ 1.7	$ (1,058.6)	$ 250.1	$ 1,835.9	$ (92.1)	$ 11.0	$ 5.7
Balance (in shares) at Sep. 30, 2022			147,366,634	27,931,042